Az immunterápia szerepe az uroteliális daganatok modern kezelésében

Translated title of the contribution: The role of immunotherapy in the modern treatment of urothelial carcinoma

Anikó Maráz, L. Géczi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

By the emergence of modern immunotherapies with active agents like PD-1 (nivolumab, pembrolizumab) and PD-L1 immune checkpoint blockers (atezolizumab, avelumab, durvalumab), new therapeutic options have become available for the treatment of patients with locally advanced and metastatic urothelial carcinoma. According to the recent publications, they have been effective in case of progression after platinum therapy, in or after second-line and in firstline therapies for cisplatin ineligible patients, respectively. Patient survival and tumor response data are very promising; in particular stages, they seem to be more effective than the previously administered chemotherapies. Their toxicity profiles also appear to be more favorable. Immunological side effects are rare; their identification and management require preparedness and multidisciplinary thinking. Current and ongoing trials are investigating the combinations of new remedies with other immunotherapeutic agents (e.g., CTLA-4 inhibitor ipilimumab, tremelimumab) or chemotherapies as well as trying to identify biomarkers in order to further increase effectiveness. In our review, we summarize the recently published data about urothelial carcinoma therapy and give a brief overview of the ongoing clinical trials.

Original languageHungarian
Pages (from-to)139-146
Number of pages8
JournalMagyar onkologia
Volume61
Issue number2
Publication statusPublished - Jun 6 2017

Fingerprint

Immunotherapy
Carcinoma
Therapeutics
Active Immunotherapy
Drug Therapy
Platinum
Cisplatin
Meta-Analysis
Biomarkers
Survival
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az immunterápia szerepe az uroteliális daganatok modern kezelésében. / Maráz, Anikó; Géczi, L.

In: Magyar onkologia, Vol. 61, No. 2, 06.06.2017, p. 139-146.

Research output: Contribution to journalArticle

@article{9b44f140275545cc970a418c7af3333f,
title = "Az immunter{\'a}pia szerepe az uroteli{\'a}lis daganatok modern kezel{\'e}s{\'e}ben",
abstract = "By the emergence of modern immunotherapies with active agents like PD-1 (nivolumab, pembrolizumab) and PD-L1 immune checkpoint blockers (atezolizumab, avelumab, durvalumab), new therapeutic options have become available for the treatment of patients with locally advanced and metastatic urothelial carcinoma. According to the recent publications, they have been effective in case of progression after platinum therapy, in or after second-line and in firstline therapies for cisplatin ineligible patients, respectively. Patient survival and tumor response data are very promising; in particular stages, they seem to be more effective than the previously administered chemotherapies. Their toxicity profiles also appear to be more favorable. Immunological side effects are rare; their identification and management require preparedness and multidisciplinary thinking. Current and ongoing trials are investigating the combinations of new remedies with other immunotherapeutic agents (e.g., CTLA-4 inhibitor ipilimumab, tremelimumab) or chemotherapies as well as trying to identify biomarkers in order to further increase effectiveness. In our review, we summarize the recently published data about urothelial carcinoma therapy and give a brief overview of the ongoing clinical trials.",
author = "Anik{\'o} Mar{\'a}z and L. G{\'e}czi",
year = "2017",
month = "6",
day = "6",
language = "Hungarian",
volume = "61",
pages = "139--146",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - Az immunterápia szerepe az uroteliális daganatok modern kezelésében

AU - Maráz, Anikó

AU - Géczi, L.

PY - 2017/6/6

Y1 - 2017/6/6

N2 - By the emergence of modern immunotherapies with active agents like PD-1 (nivolumab, pembrolizumab) and PD-L1 immune checkpoint blockers (atezolizumab, avelumab, durvalumab), new therapeutic options have become available for the treatment of patients with locally advanced and metastatic urothelial carcinoma. According to the recent publications, they have been effective in case of progression after platinum therapy, in or after second-line and in firstline therapies for cisplatin ineligible patients, respectively. Patient survival and tumor response data are very promising; in particular stages, they seem to be more effective than the previously administered chemotherapies. Their toxicity profiles also appear to be more favorable. Immunological side effects are rare; their identification and management require preparedness and multidisciplinary thinking. Current and ongoing trials are investigating the combinations of new remedies with other immunotherapeutic agents (e.g., CTLA-4 inhibitor ipilimumab, tremelimumab) or chemotherapies as well as trying to identify biomarkers in order to further increase effectiveness. In our review, we summarize the recently published data about urothelial carcinoma therapy and give a brief overview of the ongoing clinical trials.

AB - By the emergence of modern immunotherapies with active agents like PD-1 (nivolumab, pembrolizumab) and PD-L1 immune checkpoint blockers (atezolizumab, avelumab, durvalumab), new therapeutic options have become available for the treatment of patients with locally advanced and metastatic urothelial carcinoma. According to the recent publications, they have been effective in case of progression after platinum therapy, in or after second-line and in firstline therapies for cisplatin ineligible patients, respectively. Patient survival and tumor response data are very promising; in particular stages, they seem to be more effective than the previously administered chemotherapies. Their toxicity profiles also appear to be more favorable. Immunological side effects are rare; their identification and management require preparedness and multidisciplinary thinking. Current and ongoing trials are investigating the combinations of new remedies with other immunotherapeutic agents (e.g., CTLA-4 inhibitor ipilimumab, tremelimumab) or chemotherapies as well as trying to identify biomarkers in order to further increase effectiveness. In our review, we summarize the recently published data about urothelial carcinoma therapy and give a brief overview of the ongoing clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=85047901163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047901163&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 139

EP - 146

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 2

ER -